ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

13 links0 made here, not in the record24 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05867121A Study to Evaluate Safety,Pharmacokinetics, &Activity of RO7496353 inCombination With aCheckpoint Inhibitor Withor Without Standard-of-careChemotherapy inGenentech, Inc.Phase 1 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionStomach NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termCarcinoma, Transitional CellThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termDRUGSINT011893Entry “RO7496353”, read by our name r…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAtezolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerCapecitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundTegafurEntry “S-1”, read by our name rule›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundGimeracilEntry “S-1”, read by our name rule›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundOxonic AcidEntry “S-1”, read by our name rule›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerOxaliplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAlbumin-Bound PaclitaxelEntry “Nab-paclitaxel”, read by our n…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundGemcitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

INT011893

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “RO7496353”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Background
Background · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2INT011893Claude Opus 5.5BackgroundCurrent
Nov 2AtezolizumabClaude Opus 5.5Background · partnerCurrent
Nov 2CapecitabineClaude Opus 5.5BackgroundCurrent
Nov 2TegafurClaude Opus 5.5BackgroundCurrent
Nov 2GimeracilClaude Opus 5.5BackgroundCurrent
Nov 2Oxonic AcidClaude Opus 5.5BackgroundCurrent
Nov 2NivolumabClaude Opus 5.5Background · partnerCurrent
Nov 2OxaliplatinClaude Opus 5.5BackgroundCurrent
Nov 2Albumin-Bound PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2GemcitabineClaude Opus 5.5BackgroundCurrent
Nov 14Carcinoma, Non-Small-Cell LungRule based · condition-kind ruleFinest filed termCurrent
Nov 14Stomach NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Carcinoma, Transitional CellRule based · condition-kind ruleFinest filed termCurrent
Nov 18INT011893Rule based · role ruleBackgroundAgrees
Nov 18AtezolizumabRule based · role ruleBackgroundAgrees
Nov 18CapecitabineRule based · role ruleBackgroundAgrees
Nov 18TegafurRule based · role ruleBackgroundAgrees
Nov 18GimeracilRule based · role ruleBackgroundAgrees
Nov 18Oxonic AcidRule based · role ruleBackgroundAgrees
Nov 18NivolumabRule based · role ruleBackgroundAgrees
Nov 18OxaliplatinRule based · role ruleBackgroundAgrees
Nov 18Albumin-Bound PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18GemcitabineRule based · role ruleBackgroundAgrees
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.